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Purpose: To determine the association of age-related maculopathy susceptibility 2 (ARMS2) gene polymorphisms with
the phenotype of typical neovascular age-related macular degeneration (tAMD) and polypoidal choroidal vasculopathy
(PCV) and the effects of photodynamic therapy (PDT).
Methods: The single nucleotide polymorphisms at rs10490924 (A69S) in ARMS2 of 68 tAMD and 119 PCV patients
who underwent PDT were genotyped using the TaqMan assay. The baseline best corrected visual acuity (BCVA) and
lesion size were compared among the three genotypes at rs10490924. A multivariate regression analysis was performed
to evaluate the influence of the baseline BCVA, greatest linear dimension (GLD), and lesion phenotype (tAMD or PCV)
on the association of rs10490924 with the BCVA 12 months after the first PDT.
Results: The mean lesion size was significantly different among the GG, GT, and TT genotypes at rs10490924 in the
PCV group, although no significant differences were detected in the tAMD group. PCV patients with a G allele had
significantly better vision at 3 months after the initial PDT. tAMD patients with a TT genotype had significantly poorer
vision at 12 months after the first PDT. In the multivariate regression analysis, the additive model of the G allele at
rs10490924 was associated with a significantly better BCVA 12 months after the first PDT in tAMD and PCV patients.
Conclusions: ARMS2 variants are likely associated with the phenotype and the effects of PDT in tAMD and PCV.
Age-related macular degeneration (AMD) is a leading
cause of central vision loss in the elderly in industrialized
countries [1]. The number of patients with AMD has increased
remarkably over the years, and further increases in patients
with severe visual impairment due to AMD are anticipated
[2].  Advanced  AMD  is  clinically  classified  into  atrophic
AMD and exudative AMD. Exudative AMD is further sub-
classified into typical neovascular AMD (tAMD), polypoidal
choroidal  vasculopathy  (PCV),  and  retinal  angiomatous
proliferation  [1].  These  phenotypes  are  known  to  have
different characteristics in their natural courses and responses
to  interventions,  such  as  photodynamic  therapy  [3,4]  and
antivascular endothelial growth factor (VEGF) therapy [5],
although the reasons are unknown. Recently, several genetic
association studies were conducted to explain the different
characteristics among the phenotypes of exudative AMD [6,
7]and their susceptibility to several interventions, including
photodynamic therapy [8]. A report suggested that genetic
variants  of  rs10490924  (A69S)  in  the  age-related
maculopathy susceptibility 2 (ARMS2) gene were associated
with lesion size in PCV cases [9]; however, no replication
studies have been reported to date.
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PCV is known to have a better response to photodynamic
therapy (PDT) than tAMD [3,4], but the reason for this is not
understood.  Moreover,  there  is  some  heterogeneity  in  the
response to PDT among PCV patients [10]. Recent reports
have  evaluated  the  association  of  genetic  variants  of
rs10490924 (A69S) in the ARMS2 gene with the effects of
PDT in neovascular AMD, but a positive association was not
found [11,12]. However, a more recent report demonstrated
the association of rs10490924 variants with the effects of PDT
in Japanese PCV patients [13,14]. They suggested that more
studies are needed to confirm their findings.
In  this  study  we  investigated  the  association  of
rs10490924 (A69S) in ARMS2 with the phenotypes and visual
outcomes of PDT in tAMD and PCV patients in our Japanese
cohort.
METHODS
Study  participants:  This  study  was  approved  by  the
Institutional Review Board at the Kobe University Graduate
School of Medicine and was conducted in accordance with the
Declaration  of  Helsinki.  Written  informed  consent  was
obtained  from  all  subjects.  All  cases  in  this  study  were
Japanese  individuals  recruited  from  the  Department  of
Ophthalmology at Kobe University Hospital in Japan.
One hundred and eighty-seven consecutive patients with
68 tAMD (mean age±standard deviation [SD], 76±7 years;
ratio of men to women, 53:15) and 119 PCV (mean age±SD,
73±8 years; ratio of men to women, 96:23) who underwent
Molecular Vision 2011; 17:977-982 <http://www.molvis.org/molvis/v17/a108>
Received 7 December 2010 | Accepted 15 April 2011 | Published 20 April 2011
© 2011 Molecular Vision
977PDT  and  accepted  DNA  sampling  were  retrospectively
included  in  this  study.  All  patients  received  ophthalmic
examinations,  including  visual  acuity  measurements,  slit-
lamp biomicroscopy of the fundi, color fundus photography,
optical coherence tomography, fluorescein angiography, and
indocyanine green angiography (ICG). The visual acuities
were determined using a Landolt C chart and were converted
to  a  logarithm  of  the  minimum  angle  of  resolution  for
calculations. To classify the patients clearly into tAMD and
PCV subgroups, the differential diagnoses were based on ICG
[15].  All  AMD  patients  had  clear  images  of  choroidal
neovascular  networks  on  ICG.  The  PCV  cases  showed  a
choroidal origin of their polypoidal lesions, typically with
vascular networks in the posterior poles on ICG and subretinal
orange-reddish protrusions corresponding to the polypoidal
lesions  on  ICG.  Those  patients  who  received  any  prior
treatment for AMD were not included in this study.
Photodynamic  therapy:  All  patients  in  this  study  were
followed up for at least 12 months after their first session of
PDT. PDT was performed with standard procedures described
previously [16]. The lesion status was assessed every three
months, and treatments were performed again when serious
retinal  detachment,  hemorrhage,  or  macular  edema  was
recognized  and  accompanied  by  a  leakage  on  fluorescein
angiography (FA) or a defined lesion was observed on ICG.
No  patients  in  this  study  received  other  treatments  or
combined therapy during the follow-up period.
Genotyping:  Genomic  DNA  was  extracted  from  the
peripheral blood using QIAmp DNA Blood Maxi Kit (Qiagen,
Hilden,  Germany).  Genotyping  was  performed  using
TaqMan® single nucleotide polymorphism (SNP) genotyping
assays or Custom TaqMan® SNP genotyping assays (Applied
Biosystems, Foster City, CA) on a StepOnePlus™ Real-Time
PCR System (Applied Biosystems) in accordance with the
supplier’s recommendations.
Indices compared: The mean age, gender, lesion size (greatest
linear  dimension  [GLD])  based  on  FA  findings  and  the
baseline best corrected visual acuity (BCVA) were compared
among the three genotypes of rs10490924 in ARMS2. These
parameters  were  measured  for  each  case  under  masked
conditions for genotype. As outcomes of the PDT, the BCVA
until 12 months after the initial PDT and the number of PDTs
performed during the first 12 months of the treatment term
were evaluated.
Statistical analysis: The parameters were compared among
three genotypes using an χ2 test for gender and a Kruskal–
Wallis test for the indices. For the time-course analysis, two
time points in each genotype were compared using a paired t
test  (two  tailed).  P  values<0.05  were  considered  to  be
statistically significant.
RESULTS
The clinical details of the tAMD and PCV patients stratified
by the genotypes of rs10490924 in ARMS2 are listed in Table
1 and Table 2, respectively. Patients with a TT genotype
showed a significantly larger mean lesion size than those with
GG  and  GT  genotypes  in  the  PCV  group.  In  the  tAMD
patients, the mean lesion size tended to increase with the
number  of  T  alleles,  although  there  was  no  statistical
significance.
The mean age, gender, and pretreatment BCVA were not
different among the three genotypes in the tAMD and PCV
groups.  The  number  of  PDT  sessions  per  year  tended  to
increase with the number of T alleles in the tAMD and PCV
groups, but no statistical significance was detected. The mean
BCVA at 12 months after the first PDT was significantly
better for the GG and GT genotypes than the TT genotype in
the PCV patients. In the tAMD patients, the mean BCVA
tended to be better with an increasing number of G alleles at
12 months after the first PDT, although there was no statistical
significance.  However,  the  change  of  BCVA  from  the
baseline was significantly better for the GG and GT genotypes
than the TT genotype in the tAMD and PCV patients. In the
time-course  analysis,  the  PCV  patients  with  GG  and  GT
genotypes showed a significant improvement in their mean
BCVA at 3, 6, and 12 months post-initial PDT (Figure 1). In
contrast, the tAMD patients with a TT genotype showed a
significant worsening of their mean BCVA at 12 months post-
TABLE 1. CLINICAL DETAILS OF THE TYPICAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (TAMD) PATIENTS STRATIFIED BY THE GENOTYPE
OF RS10490924 IN THE AGE-RELATED MACULOPATHY SUSCEPTIBILITY 2 (ARMS2) GENE.
n=68 G/G G/T T/T P
Gender (female/male) 0/8 9/25 6/20 0.26†
Age (mean±SD, years) 76±5 76±6 76±8 0.87*
GLD (mean±SD, μm) 3063±972 3358±1206 3950±1715 0.37*
Number of PDT sessions/year (mean±SD) 1.6±0.9 1.9±1.0 2.1±1.0 0.57*
Baseline BCVA log MAR (mean±SD) 0.87±0.51 0.76±0.36 0.78±0.42 0.96*
12Mo BCVA log MAR (mean±SD) 0.66±0.40 0.84±0.49 1.03±0.39 0.09*
12Mo-Baseline BCVA log MAR (mean±SD) −0.21±0.32 0.07±0.51 0.25±0.42 0.01*
        Abbreviations: GLD represents greatest linear dimension, PDT represents photodynamic therapy, BCVA represents best-
        corrected visual acuity, Mo represents month. † χ2 test, * Kruskal–Wallis test.
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978initial  PDT  (Figure  2).  To  evaluate  the  effects  of  age,
pretreatment  BCVA,  GLD,  PDT  frequency,  and  lesion
phenotype (tAMD or PCV), which may influence the effects
of  PDT  [7],  we  performed  stepwise  multiple  regression
analyses with backward elimination methods, including those
factors in addition to the number of risk alleles as explanatory
variables.  The  results  of  this  analysis  conserved  the
significance of the association of rs10490924 (A69S) with the
improvement of the 12 month BCVA after the first PDT
(Table 3).
DISCUSSION
We genotyped the well recognized SNP in ARMS2 in tAMD
and PCV patients who underwent PDT and found that the
genotype at rs10490924 (A69S) in ARMS2 was significantly
associated with the lesion size in PCV patients and the visual
outcome in tAMD and PCV patients at 12 months after their
first  PDT.  Namely,  patients  with  more  G  alleles  at
rs10490924 showed better BCVA values until 12 months after
the first PDT.
Recent  genetic  association  studies  have  performed
comparative assessments for the association of rs10490924
(A69S)  in  ARMS2  among  three  different  phenotypes  of
exudative  AMD:  tAMD,  PCV  [17-20],  and  retinal
angiomatous proliferation [18]. These studies found that the
association of rs10490924 (A69S) in ARMS2 was consistently
higher  in  tAMD  patients  than  in  PCV  patients,  which
suggested  heterogeneities  in  the  association  of  this  SNP
within  the  AMD  phenotype  spectrum.  The  association  of
ARMS2  with  the  lesion  size  in  PCV  has  been  reported
previously,  and  that  study  emphasized  the  necessity  of
replication studies with other cohorts [9]. In the present study
we also found an association of ARMS2 with the lesion size
in PCV that supported the previous report. Although a few
previous reports from Western countries failed to demonstrate
an  association  of  ARMS2  with  the  effects  of  PDT  in
neovascular AMD [11,12], we found that the coding variants
TABLE 2. CLINICAL DETAILS OF POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) PATIENTS STRATIFIED BY THE GENOTYPE OF RS10490924 IN THE AGE-
RELATED MACULOPATHY SUSCEPTIBILITY 2 (ARMS2) GENE.
n=119 G/G G/T T/T P
Gender (female/male) 3/21 8/38 12/37 0.43†
Age (mean±SD, years) 73±9 73±7 72±8 0.88*
GLD (mean±SD, μm) 3475±1615 3051±1550 4342±1737 0.00073*
Number of PDT sessions/year (mean±SD) 1.5±0.7 1.5±0.5 1.6±0.7 0.75*
Baseline BCVA log MAR (mean±SD) 0.79±0.41 0.62±0.32 0.65±0.34 0.27*
12Mo BCVA log MAR (mean±SD) 0.59±0.50 0.47±0.44 0.71±0.41 0.014*
12Mo-Baseline BCVA log MAR (mean±SD) −0.20±0.39 −0.15±0.45 0.06±0.41 0.012*
       Abbreviations: GLD represents greatest linear dimension, PDT represents photodynamic therapy, BCVA represents best-
       corrected visual acuity, Mo represents month. † χ2 test, * Kruskal–Wallis test.
Figure 1. Influence of the genotype at
rs10490924  (A69S)  in  age-related
maculopathy susceptibility 2 on the time
course  of  the  logMAR  baseline  best
corrected visual acuity (BCVA) value
was  evaluated  in  all  polypoidal
choroidal vasculopathy patients treated
by  photodynamic  therapy  (PDT).  All
values are presented as means±standard
error of the mean (SEM). The GG and
GT  genotypes  show  significant
improvements in their mean BCVA at 3,
6, and 12 months (p<0.05, ** p<0.01,
*** p<0.001).
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979at  rs10490924  (A69S)  in  ARMS2  were  significantly
associated with the visual outcome at 12 months post-PDT in
Japanese tAMD and PCV patients. This may be explained by
differences  in  the  proportion  of  AMD  phenotypes  (i.e.,
neovascular AMD versus PCV) in different ethnic groups or
explained by differences in the baseline BCVA between the
studies, which may influence the post-PDT BCVA [4]. Our
results were consistent with previous reports that suggested a
positive association of this SNP with the outcome of PDT in
PCV  [13,14],  a  major  subtype  of  Japanese  AMD  [21].
Although we could not detect a significant association of the
genotype at rs10490924 with the lesion size in tAMD patients,
there was a tendency for the lesion size to increase with an
increasing number of T alleles. We hypothesized that the
statistical power was not sufficient to detect a significant
association of rs10490924 (A69S) in ARMS2 with the lesion
size of tAMD patients in our cohort and that the association
of ARMS2 may be independent of the AMD phenotype (tAMD
or PCV). In fact, the multivariate regression analysis revealed
that  the  number  of  risk  alleles  at  rs10490924  was  an
independent factor significantly associated with an improved
BCVA at 12 months after PDT. A recent study demonstrated
the significant association of SNP rs11200638 in the promoter
region  of  the  high-temperature  requirement  factor  A1
(HTRA1) gene with the visual outcome after PDT in Japanese
exudative AMD patients [8]. Their results were similar to our
findings, probably because SNP rs11200638 has a very high
linkage disequilibrium with rs10490924 in ARMS2 [17].
The role of ARMS2 in PDT is unknown. Recent reports
demonstrated that ARMS2 can affect the lesion size in PCV
[9], which may influence the visual outcome at 12 months
post-PDT [4]. However, in the present study the results of the
multivariate analysis showed that the association of the coding
variants in ARMS2 with the effects of PDT was independent
of  the  pretreatment  GLD,  BCVA,  and  lesion  phenotype.
Kanda et al. reported that ARMS2 distributes to the outer
membrane of the mitochondria and may be involved in the
regulation of oxidative stress [22]. Reactive oxygen species
play a key role by which PDT affects neovascular endothelial
cells,  followed  by  thrombosis  and  the  occlusion  of
Figure 2. Influence of the genotype at
rs10490924  (A69S)  in  age-related
maculopathy susceptibility 2 on the time
course  of  the  logMAR  best-corrected
visual  acuity  (BCVA)  value  was
evaluated in all typical neovascular age-
related  macular  degeneration  (tAMD)
patients  treated  by  photodynamic
therapy (PDT). All values are presented
as  means±standard  error  of  the  mean
(SEM).  The  TT  genotype  shows  a
significant  worsening  of  their  mean
BCVA at 12 months (** p<0.01).
TABLE 3. RESULTS OF THE STEPWISE MULTIPLE REGRESSION ANALYSIS. PROGNOSTIC FACTORS FOR THE BASELINE BEST-CORRECTED VISUAL ACUITY (BCVA) AT
12 MONTHS AFTER PHOTODYNAMIC THERAPY (PDT) INCLUDING ALL PHENOTYPES.
Prognostic factors SPRC SEM p value 95%CI
Number of risk (T) alleles at rs10490924 in ARMS2 0.17 0.041 0.0095 0.027–0.19
Number of PDTs 0.16 0.036 0.0184 0.015–0.16
GLD 0.15 0.00 0.0266 0.000–0.0001
Lesion phenotype (tAMD=0, PCV=1) −0.21 0.062 0.0017 −0.32–0.075
Baseline BCVA logMAR −0.4 0.080 <0.0001 −0.65–0.33
        Abbreviations: SPRC represents standardized partial regression coefficient, SEM represents standard error of the mean, CI
        represents Confidence interval, GLD represents greatest linear dimension, BCVA represents best-corrected visual acuity.
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980neovascular  tracts  [23].  However,  further  studies  will  be
needed to elucidate the role of ARMS2 in the pathogenesis of
tAMD and PCV.
The  limitation  of  the  present  study  is  the  relatively
smaller sample size and retrospective nature. A prospective
study for the outcome of PDT with a larger population will be
needed to disclose further associations of ARMS2 variants
with the effect of PDT in tAMD and PCV patients.
Since PDT is known to induce several gene expression
changes in the retina–choroidal complex [23,24], the detailed
mechanisms by which multiple genes interact with each other
close to the choroidal neovascularization (CNV) is poorly
understood. However, the present genetic association study
suggests some clinical possibilities that can be applied for
personalized therapies in individual tAMD and PCV patients.
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